reported that a beta-adrenergic agonist inhibited the mitotic rate in colonic carcinomas induced by dimethylhydrazine (DMH). Tutton (1975) also reported that cholinoceptor stimulation, either by injection of carbachol or by inhibition of acetylcholinesterase, resulted in an increase in the mitotic rate in the crypts of Lieberkiihn in rat jejunum. These findings suggested that the autonomic nervous system influences growth of colonic tumours. Therefore, in the present work, we examined the effects of prolonged treatment of rats with the beta-adrenergic agonist isoproterenol, and the acetylcholinesterase inhibitor neostigmine from before the time of injection of a carcinogen on the development of colonic tumours.
were killed at the end of week 40. The presence of tumour was verified by microscopy. Labelling indices of the colonic mucosa in proximal and distal parts of the colon and/or the colonic tumours were examined in weeks 7 and 40. In week 7, the rats were killed 24 h after the last injection of AOM. The labelling indices of the colonic mucosa and tumours were measured with kit for immunohistochemical analysis of bromodeoxyuridine (BrdU) incorporation (Becton Dickinson, Mountain View, CA), by the modified method described by Tada et al. (1985) . The results were analyzed by Student's t-test, the chi-square test or Fisher's exact probability test. Data are given as mean+s.e. 'Significant' indicates a calculated P value of less than 0.05. Epithelial proliferation in the colon may be regulated by the autonomic nervous system. In the present work, we found that prolonged administration of the beta-adrenergic agonist isoproterenol from before AOM-treatment resulted in a significant decrease in the incidence and number of colonic tumours in week 40. Tutton and Barkla (1977) found that in rats, a beta-adrenergic agonist inhibited the mitotic rate in DMH-induced colonic carcinomas. More recently, Chang (1985) found that isoproterenol treatment soon after each weekly injection of DMH inhibited the initiation phase of colonic carcinogenesis. These findings indicate that the inhibitory effect of the beta-adrenergic agonist on the development of colonic tumours may be related to its effect in decreasing the proliferation of colonic tumours. However, our results were somewhat different from those of Kennedy et al. (1983) showing an inhibitory effect of isoproterenol on intestinal cell proliferation. This difference in findings may be attributable to the difference in the methods of the cytokinetic studies. Gurkalo and Volfson (1982) examined the effects of nicotine on the development of gastric cancers induced by N-methyl-N'-nitro-N-nitrosoguanidine and suggested that compounds that enhance cholinergic functions inhibit carcinogenesis. In the present work, we found that prolonged administration of an inhibitor of acetylcholinesterase, neostigmine, resulted in a significant decrease in the incidence and number of colonic tumours in week 40. We also found that neostigmine significantly decreased the labelling indices of colonic mucosa during AOM-treatment. This effect of neostigmine in decreasing the labelling indices during AOMtreatment may be related to its effect in inhibiting development of colonic tumours. Tutton and Barkla (1976) examined the colonic mucosal abnormalities in carcinogen-treated rats, and found that a slight fall in overall crypt cell metaphase rate in the descending colon of rats treated with DMH. Pozharisski et al. (1982) found that the proportion of morphologically abnormal mitoses increased from 4% in normal mucosae to 50-60% in DMH-treated colon. In the present work, we found that AOM had a stimulating effect on colonic cell proliferation. We also found that the effects of neostigmine on cell proliferation were different during hnd after carcinogen treatment. In the present work, neostigmine decreased label-BJC-F M. TATSUTA et al. 
